DiscGenics Inc., a clinical stage biotechnology company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, has been granted Fast Track designation from the FDA for its investigational cell therapy, IDCT, currently being evaluated in regulator-allowed clinical trials in the U.S. and Japan for the reduction in pain and disability associated with degenerative disc disease (DDD), a major cause of chronic low back pain.
 
Fast Track is a special regulatory designation that companies can apply for once they have sufficient preclinical and clinical evidence that a product may be able to treat an unmet medical need for a serious medical condition. With this designation, Sponsors may benefit from early and frequent communication with FDA, eligibility for Accelerated Approval and Priority Review programs, as well as a Rolling Review application process for marketing licensure.
 
“We are thrilled to receive Fast Track designation for IDCT as it recognizes the extremely compelling preclinical¹ and safety data we have generated for IDCT through our robust research and development and clinical programs, and underscores FDA’s acknowledgement of low back pain as a serious medical condition with a profound lack of treatment options,” said Flagg Flanagan, chairman and CEO of DiscGenics Inc. “This Fast Track designation reinforces our commitment to working with regulators to identify ways to accelerate development and expedite approval of the therapy within existing regulatory frameworks to make IDCT available to patients as quickly as possible.”
 
IDCT is a homologous, allogeneic, injectable cell therapy that utilizes biomedically engineered progenitor cells, known as Discogenic Cells, that have been derived from intervertebral disc tissue to offer a non-invasive, potentially regenerative solution for the treatment of mild to moderate DDD. As a manufactured allogeneic cell therapy, IDCT is regulated by FDA’s Center for Biologics Evaluation and Research (CBER) under Section 351 of the Public Health Service Act (PHSA). As a result, DiscGenics is adhering to the rigors of a regulated drug pathway that require the Company to not only prove that the product has a therapeutic effect through clinical evaluation, but also that it meets critical safety standards and is produced consistently from lot to lot through adherence to current good manufacturing practice (cGMP) standards for a cell therapy.
 
DiscGenics is conducting two parallel prospective, randomized, double-blinded, controlled, multicenter clinical trials of IDCT in the U.S. and Japan. IDCT is being evaluated in the U.S. under an investigational new drug (IND) allowance by the FDA and will be regulated as a drug-biologic through a biologics license application (BLA). In Japan, the trial is supported by a Clinical Trial Notification (CTN) approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Primary outcome measures include safety and reduction in pain. Secondary outcome measures include reduction in disability and radiographic improvement. Importantly, the U.S. study has shown safety in the first cohort of patients. For both studies, enrollment is ongoing.

Reference:
¹ Silverman, L., Dulatova, G., Tandeski, T., Erickson, I., Lundell, B., Toplon, D., Wolff, T., Howard, A., Chintalacharuvu, S., Foley, K. In Vitro and In Vivo Evaluation of Discogenic Cells, An Investigational Cell Therapy for Disc Degeneration. The Spine Journal, published online 2019 Aug 20.